Health Care Supplies

Bausch + Lomb

Bausch + Lomb to Host R&D Contact Lens Project Webinar

Bausch + Lomb released FY2026 Q1 earnings on April 29 Pre-Market (EST), actual revenue USD 1.244 B (forecast USD 1.216 B), actual EPS USD -0.2 (forecast USD -0.1475)

Bausch + Lomb to Release FY2026 Q1 Earnings on April 29 Pre-Market EST, Forecast Revenue USD 1.215 B, EPS USD -0.1475

Bausch + Lomb released FY2025 annual earnings on February 18 Pre-Market EST, actual revenue USD 0 (forecast USD 5.079 B), actual EPS USD 0 (forecast USD -0.744)

Bausch + Lomb released FY2025 Q4 earnings on February 18 Pre-Market (EST), actual revenue USD 1.405 B (forecast USD 1.385 B), actual EPS USD -0.1701 (forecast USD 0.1375)

Bausch + Lomb to Release FY2025 Q4 Earnings on February 18, 2026 Pre-Market EST, Forecast Revenue USD 1.385 B, EPS USD 0.1375

Bausch + Lomb Executives to Speak at JPM Healthcare Conference

Needham Maintains Hold Rating on Bausch + Lomb and Adjusts Financial Model

Wells Fargo analyst reiterates Bausch + Lomb hold rating, target price at $17.00

US Bank Maintains Sell Rating on Bausch + Lomb

Bausch + Lomb Outlines Three-Year Growth Strategy

Bausch + Lomb Highlights Strong Revenue Growth and Maintains Full-Year Guidance

Bausch + Lomb released FY2025 9 Months earnings on October 29 After-Market (EST), actual revenue USD 3.696 B, actual EPS USD -0.8609

Bausch + Lomb released FY2025 Q3 earnings on October 29 After-Market EST, actual revenue USD 1.281 B (forecast USD 1.278 B), actual EPS USD -0.08 (forecast USD -0.072)

Thomas Stephan Rates Bausch + Lomb Corporation as Hold

Bausch + Lomb to release FY2025 Q3 earnings on October 29 After-Market EST, forecast revenue USD 1.277 B, EPS USD -0.07

Jana Partners Builds Stake in Cooper Companies and Pushes for Potential Contact Lens Unit Merger

Bausch & Lomb Corp Publishes Q2 2025 Earnings Report

Bausch + Lomb released FY2025 Semi-Annual earnings on July 30 During-Market EST, actual revenue USD 2.415 B, actual EPS USD -0.78

Bausch + Lomb released FY2025 Q2 earnings on July 30 During-Market EST, actual revenue USD 1.278 B (forecast USD 1.256 B), actual EPS USD -0.18 (forecast USD -0.188)

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

BLCO

Bausch + Lomb shareholders elected directors at the annual meeting on May 20, 2026, to serve until the 2027 meeting. They also supported a non-binding advisory say-on-pay resolution and appointed PricewaterhouseCoopers as the independent auditor through the 2027 meeting, authorizing the board to set its remuneration.

PUBT

Bausch + Lomb shareholders elected directors at annual meeting

Bausch + Lomb Announces 2026 Annual Meeting of Shareholder Results | BLCO Stock News

StockTitan

Bausch + Lomb Announces 2026 Annual Meeting of Shareholder Results | BLCO Stock News

09:55 AM EST - Bausch + Lomb Corporation : Announced the U.S. launch of PreserVision AREDS3 eye vitamins, which combine the clinically proven AREDS2 nutrients recommended by the NEI to help reduce the risk of moderate-to-advanced AMD progression with a unique B-vitamin complex. Built on decades of leadership in AREDS-based vitamins, PreserVision AREDS3 is the most advanced PreserVision formula, intended to support a broader range of people, including those in earlier stages. Bausch + Lomb Corporation shares T.BLCO are trading up $0.16 at $22.54.

Baystreet

Stocks in Play: Bausch + Lomb Corporation

Bausch + Lomb Announces Second R&D “Teach-in” Webinar | BLCO Stock News

Bausch + Lomb Announces Second R&D “Teach-in” Webinar | BLCO Stock News

H.C. Wainwright analyst Yi Chen has reiterated a Buy rating on Bausch + Lomb Corporation (BLCO) with a price target of $20.00. Chen, who focuses on the Healthcare sector, has an average return of 0.2% and a 40.89% success rate on his stock recommendations. Additionally, Citi's Joanne Wuensch also issued a Buy rating for Bausch + Lomb, while Stifel Nicolaus maintained a Hold rating on the same day.

Tip Ranks

Ocular Therap

Opko Health

Caredex

Citigroup

Stifel Financial

CITIGROUP INC 6.250 NON CUM SER II PFD WI

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

H.C. Wainwright Remains a Buy on Bausch + Lomb Corporation (BLCO)

Stifel Nicolaus analyst Thomas Stephan has maintained a Hold rating on Bausch + Lomb Corporation (BLCO) with a price target of $16.00. He has an average return of 2.1% and a 40% success rate on his stock recommendations. Additionally, Barclays also issued a Hold rating, while Citi maintained a Buy rating on the company.

TransMedics

Glaukos

Alphatec

Barclays

Stifel Nicolaus Keeps Their Hold Rating on Bausch + Lomb Corporation (BLCO)

Needham analyst David Saxon has maintained a Hold rating on Bausch + Lomb (BLCO) stock due to strong Q1 performance, including revenue and EBITDA exceeding expectations, and positive momentum in the pharmaceuticals division. However, uncertainty surrounding the company's planned spin-off from Bausch Health Companies tempers this outlook. Barclays also reiterated a Hold rating with a $20.00 price target.

Bausch Health

Bausch + Lomb: Solid Q1 Beat and Pharma Momentum Offset by Spin-Off Uncertainty, Supporting Hold Rating

Bausch + Lomb(BLCO.US)

Bausch + Lomb shareholders elected directors at annual meeting

Bausch + Lomb Announces 2026 Annual Meeting of Shareholder Results | BLCO Stock News

Stocks in Play: Bausch + Lomb Corporation

Bausch + Lomb Announces Second R&D “Teach-in” Webinar | BLCO Stock News

H.C. Wainwright Remains a Buy on Bausch + Lomb Corporation (BLCO)

Stifel Nicolaus Keeps Their Hold Rating on Bausch + Lomb Corporation (BLCO)

Bausch + Lomb: Solid Q1 Beat and Pharma Momentum Offset by Spin-Off Uncertainty, Supporting Hold Rating